SCHEMBL22801611

SCHEMBL22801611

COC(=O)c1ccc(-c2n[nH]c3cc(Cl)ccc23)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 8/20 1.00
MAPK1 P28482 4/20 0.55
MAPK6 Q16659 3/20 0.50
TRPA1 O75762 1/20 0.49
NR4A2 P43354 1/20 0.49
MAPK8 P45983 1/20 0.48
MAPK10 P53779 1/20 0.48
MAPK14 Q16539 1/20 0.48
CSNK2A2 P19784 1/20 0.48
CSNK2B P67870 1/20 0.48
MAPT P10636 1/20 0.48
KDR P35968 1/20 0.47
MAPKAPK5 Q8IW41 2/20 0.47
GSK3B P49841 1/20 0.47
RHEB Q15382 1/20 0.46
MAPKAPK2 P49137 1/20 0.46
MAPKAPK3 Q16644 1/20 0.46
DHODH Q02127 1/20 0.46
PDPK1 O15530 1/20 0.46
HSP90AB1 P08238 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22819376 0.84 MAP2K4 (1.00) MAP2K4MAPK1MAPK6TRPA1MAPK14
SCHEMBL22801745 0.83 MAP2K4 (1.00) MAP2K4MAPK1MAPK6MAPK8MAPK10
SCHEMBL144396 0.81 MAP2K4 (0.68) MAP2K4TRPA1KDR
SCHEMBL22801559 0.81 MAP2K4 (0.73) MAP2K4MAPK1MAPK6TRPA1MAPKAPK5
SCHEMBL8126956 0.81 MAPK1 (0.72) MAP2K4MAPK1MAPK6MAPK8MAPK10
SCHEMBL30609861 0.79 MAP2K4 (0.65) MAP2K4MAPK1NR4A2MAPTGSK3B
SCHEMBL4791992 0.79 MAP2K4 (0.65) MAP2K4MAPK1NR4A2MAPTGSK3B
Hydrochloric Acid SCHEMBL6370142 0.79 MAPK10 (0.77) MAP2K4MAPK1MAPK8MAPK10MAPK14
SCHEMBL22801850 0.78 MAP2K4 (0.64) MAP2K4MAPK1NR4A2CSNK2A2CSNK2B
SCHEMBL4032441 0.77 PDPK1 (0.75) MAP2K4MAPK1MAPK6KDRMAPKAPK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11370770-B2 3-arylindazoles as selective MEK4 inhibitors NORTHWESTERN UNIVERSITY (US) 2022-06-28 US disclosed
US-11370770-B2 3-arylindazoles as selective MEK4 inhibitors NORTHWESTERN UNIVERSITY (US) 2022-06-28 US disclosed
US-20200399241-A1 3-ARYLINDAZOLES AS SELECTIVE MEK4 INHIBITORS NORTHWESTERN UNIVERSITY (US) 2020-12-24 US disclosed
US-20200399241-A1 3-ARYLINDAZOLES AS SELECTIVE MEK4 INHIBITORS NORTHWESTERN UNIVERSITY (US) 2020-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399241-A1 3-ARYLINDAZOLES AS SELECTIVE MEK4 INHIBITORS MAP4K3, MAPK4, MAP3K4 MAP2K4 39/4885MAPK1 32/4885MAPK6 42/4885
US-11370770-B2 3-arylindazoles as selective MEK4 inhibitors MAP4K3, MAPK4, MAP3K4 MAP2K4 39/4885MAPK1 32/4885MAPK6 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.